$0.50
4.83% day before yesterday
Nasdaq, Jul 25, 10:00 pm CET
ISIN
US75120L1008
Symbol
RLYB

Rallybio Corp Target price 2025 - Analyst rating & recommendation

Rallybio Corp Classifications & Recommendation:

Buy
55%
Hold
45%

Rallybio Corp Price Target

Target Price $1.02
Price $0.50
Potential
Number of Estimates 3
3 Analysts have issued a price target Rallybio Corp 2026 . The average Rallybio Corp target price is $1.02. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 6 Analysts recommend Rallybio Corp to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Rallybio Corp stock has an average upside potential 2026 of . Most analysts recommend the Rallybio Corp stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.64 0.21
67.17%
EBITDA Margin -9,432.81% -32,524.27%
244.80%
Net Margin -9,028.13% -17,068.18%
89.06%

5 Analysts have issued a sales forecast Rallybio Corp 2025 . The average Rallybio Corp sales estimate is

$210k
Unlock
. This is
75.28% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$223k 73.81%
Unlock
, the lowest is
$196k 76.94%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $640k
2025
$210k 67.17%
Unlock
2026
$0.0 100.00%
Unlock
2029
$394m 341.37%
Unlock
2030
$933m 136.90%
Unlock
2031
$1.5b 63.95%
Unlock

3 Analysts have issued an Rallybio Corp EBITDA forecast 2025. The average Rallybio Corp EBITDA estimate is

$-68.3m
Unlock
. This is
35.97% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-70.4m 39.97%
Unlock
, the lowest is
$-65.7m 30.64%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-60.4m 23.37%
2025
$-68.3m 13.20%
Unlock
2026
$-45.9m 32.84%
Unlock

EBITDA Margin

2024 -9,432.81%
2025
-32,524.27% 244.80%
Unlock

6 Rallybio Corp Analysts have issued a net profit forecast 2025. The average Rallybio Corp net profit estimate is

$-35.9m
Unlock
. This is
25.59% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-34.1m 29.28%
Unlock
, the lowest is
$-37.1m 22.99%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-57.8m 22.51%
2025
$-35.9m 37.94%
Unlock
2026
$-37.1m 3.57%
Unlock
2027
$-39.5m 6.27%
Unlock

Net Margin

2024 -9,028.13%
2025
-17,068.18% 89.06%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.33 -0.86
27.72% 35.34%
P/E negative
EV/Sales negative

6 Analysts have issued a Rallybio Corp forecast for earnings per share. The average Rallybio Corp EPS is

$-0.86
Unlock
. This is
20.37% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.82 24.07%
Unlock
, the lowest is
$-0.89 17.59%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.33 27.72%
2025
$-0.86 35.34%
Unlock
2026
$-0.89 3.49%
Unlock
2027
$-0.95 6.74%
Unlock

P/E ratio

Current -0.46 42.45%
2025
-0.58 25.60%
Unlock
2026
-0.56 3.45%
Unlock
2027
-0.53 5.36%
Unlock

Based on analysts' sales estimates for 2025, the Rallybio Corp stock is valued at an EV/Sales of

-160.62
Unlock
and an P/S ratio of
98.75
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -39.70 63.98%
2025
-160.62 304.59%
Unlock
2029
-0.09 77.34%
Unlock
2030
-0.04 57.76%
Unlock
2031
-0.02 38.95%
Unlock

P/S ratio

Current 24.42 86.81%
2025
98.75 304.47%
Unlock
2029
0.05 77.33%
Unlock
2030
0.02 57.87%
Unlock
2031
0.01 38.74%
Unlock

Current Rallybio Corp Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Jones Trading
Locked
Locked
Locked Apr 15 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Dec 03 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 22 2024
Analyst Rating Date
Locked
Jones Trading:
Locked
Locked
Apr 15 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Dec 03 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 22 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today